General
Preferred name
NIFEDIPINE
Synonyms
Nifedipine D6 ()
BAY-a-1040 D6 ()
BAY-a-1040 ()
Procardia ()
Adalat ()
Procardia XL ()
nifedipine once daily, Watson ()
Nifedipine (BAY-a-1040) ()
Calanif ()
NSC-757242 ()
Tensipine MR 20 ()
Nifopress MR ()
Angiopine 10 ()
Genalat 10 Ret ()
Hypolar XL 30 ()
Nimodrel XL ()
Fortipine LA40 ()
Coracten ()
Adalate LP ()
BAY A 1040 ()
Angiopine MR 10 ()
Adalat LA 30 ()
Coracten SR ()
Coracten XL ()
Unipine XL ()
Nifopress Ret ()
Calchan MR 20 ()
Nifedipress MR 10 ()
Coroday MR ()
Adanif XL ()
Nife-Wolff ()
Genalat 20 Ret ()
Nifedipine slow release ()
Hypolar Ret 20 ()
Calchan MR 10 ()
Adalat Cc ()
Angiopine MR 20 ()
Kentipine MR 20 ()
Nifedipine hydrochloride ()
Adalat Ret ()
Nifensar Xl ()
Calcilat ()
Adalat LA 60 ()
Valni XL ()
Adalat IC ()
Cardilate MR ()
Angiopine 40 LA ()
Nifedipress MR 20 ()
Tensipine MR 10 ()
Adipine XL ()
Angiopine 5 ()
Valni 20 Ret ()
Afeditab Cr ()
Nifedotard 20 MR ()
Slofedipine XL 30 ()
Adipine MR 10 ()
Nifedipinum ()
Hypolar Ret 10 ()
Nimodrel MR 20 ()
Neozipine XL ()
Kentipine ()
Adipine MR 20 ()
Kentipine MR 10 ()
Adalat LA 20 ()
Nifelease ()
Nifedipino ()
Adalat A.R. ()
Vasad ()
Nivaten Ret ()
Nimodrel MR 10 ()
Slofedipine XL 60 ()
Nifedipine-d6 ()
P&D ID
PD001839
CAS
21829-25-4
101539-70-2
1188266-14-9
Tags
available
drug
Approved by
FDA
First approval
1981
Drug indication
Angina pectoris
Vasodilator (coronary)
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
PD001839
NIFEDIPINE
approved
RO5
MW
346.12
HBA
7
HBD
1
RB
4
LOGP
2.18
52
38
0
79
Structure formats
SMILES
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
InChI
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
InChIkey
HYIMSNHJOBLJNT-UHFFFAOYSA-N
MOL
NIFEDIPINE RDKit 2D 25 26 0 0 0 0 0 0 0 0999 V2000 5.2500 1.2990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7500 1.2990 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3.0000 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7500 -1.2990 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.5000 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.7500 -1.2990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.5000 -2.5981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.7500 -1.2990 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -1.5000 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.0000 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.7500 1.2990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.5000 2.5981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.2803 3.3644 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -3.0000 2.5981 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -3.7500 3.8971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.7500 1.2990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.5000 2.5981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.0000 2.5981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7500 3.8971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.0000 5.1962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.5000 5.1962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.7500 3.8971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.7500 3.8971 0.0000 N 0 0 0 0 0 4 0 0 0 0 0 0 -1.5000 5.1962 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.7920 2.8182 0.0000 O 0 0 0 0 0 1 0 0 0 0 0 0 1 2 1 0 2 3 1 0 3 4 2 0 3 5 1 0 5 6 2 0 6 7 1 0 6 8 1 0 8 9 1 0 9 10 1 0 9 11 2 0 11 12 1 0 12 13 2 0 12 14 1 0 14 15 1 0 11 16 1 0 16 17 1 0 17 18 2 0 18 19 1 0 19 20 2 0 20 21 1 0 21 22 2 0 22 23 1 0 23 24 2 0 23 25 1 0 16 5 1 0 22 17 1 0 M CHG 2 23 1 25 -1 M END > <ID> PD001839 > <Name> NIFEDIPINE
Description
(extracted from source data)
DESCRIPTION One of the dihydropyridine class of drugs. (GtoPdb)
DESCRIPTION L-type Ca2+ channel blocker; vasodilator (LOPAC library)
DESCRIPTION Potent and selective GluK1 kainate agonist (Tocris Bioactive Compound Library)
DESCRIPTION Ca2+ channel blocker (L-type) (Tocriscreen Total)
Protein targets
79
9.2
7.28
CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C inhibitorantagonist BIOCHEM 24x CELL-BASED 5.8x
5
13
8.59
6.38
CACNA1C,CACN... Voltage-gated L-type calcium channel
0
6
7.82
6.33
CACNA1C,CACN... Voltage-gated L-type calcium channel blocker
0
5
7.7
5.87
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D inhibitorantagonist
4
3
7.3
6.52
CYP1A2 Cytochrome P450 1A2
7
3
6.8
TSHR Thyrotropin receptor
2
1
6.45
AMPC Beta-lactamase
0
1
6.4
TRPA1 Transient receptor potential cation channel subfamily A member 1
1
1
6.32
5.14
ADORA3 Adenosine receptor A3
2
4
6.3
CACNA1S Voltage-dependent L-type calcium channel subunit alpha-1S inhibitorantagonist
1
1
6.15
HIF1A Hypoxia-inducible factor 1-alpha
11
1
6
CACNA1F Voltage-dependent L-type calcium channel subunit alpha-1F antagonist
0
1
5.86
CCR2 C-C chemokine receptor type 2
4
1
5.82
IDO2 Indoleamine 2,3-dioxygenase 2
1
1
5.8
THPO Thrombopoietin
1
1
5.7
MYLK Myosin light chain kinase, smooth muscle
2
1
5.61
BCHE Cholinesterase
4
1
5.58
4.65
ADORA2A Adenosine receptor A2a
4
3
5.51
CYP2J2 Cytochrome P450 2J2
3
1
5.48
APBA1,CACNA1B Voltage-gated N-type calcium channel alpha-1B subunit/Amyloid beta A4 precursor protein-binding family A member 1
0
1
5.4
ACHE Acetylcholinesterase
3
1
5.4
BLM RecQ-like DNA helicase BLM
17
1
5.3
LMNA Prelamin-A/C
8
1
5.25
SMN1 Survival motor neuron protein
2
1
5.17
HTR2B 5-hydroxytryptamine receptor 2B
2
1
5.15
ABHD5,PLIN5 1-acylglycerol-3-phosphate O-acyltransferase ABHD5/Perilipin-5
0
1
5.1
CYP2C19 Cytochrome P450 2C19
5
2
5.09
KCNK2 Potassium channel subfamily K member 2
0
1
5.05
5.23
ADORA1 Adenosine receptor A1
2
4
5.02
ABHD5,PLIN1 Perilipin-1/ABHD5
0
1
5
HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2
5
1
4.97
MAPT Microtubule-associated protein tau
3
1
4.97
RORC Nuclear receptor ROR-gamma
3
1
4.96
CYP3A4 Cytochrome P450 3A4
7
5
4.96
OPRM1 Mu-type opioid receptor
6
1
4.95
NFKB1 Nuclear factor NF-kappa-B p105 subunit
27
1
4.92
SCN5A Sodium channel protein type 5 subunit alpha
2
1
4.9
GMNN Geminin
3
1
4.9
FBA Fructose-bisphosphate aldolase
0
1
4.9
KCNA7 Potassium voltage-gated channel subfamily A member 7 blocker
1
1
4.89
MAOA Amine oxidase [flavin-containing] A
8
1
4.88
HTR2C 5-hydroxytryptamine receptor 2C
2
1
4.82
ALOX15 Polyunsaturated fatty acid lipoxygenase ALOX15
10
1
4.8
CHRM1 Muscarinic acetylcholine receptor M1
2
1
4.8
ALDH1A1 Aldehyde dehydrogenase 1A1
3
1
4.8
HPGD 15-hydroxyprostaglandin dehydrogenase [NAD(+)]
4
1
4.8
CYP2C9 Cytochrome P450 2C9
6
2
4.78
MTOR Serine/threonine-protein kinase mTOR
14
1
4.78
ABCC4 ATP-binding cassette subfamily C member 4
4
1
4.73
TBXAS1 Thromboxane-A synthase
3
1
4.7
KCNA2 Potassium voltage-gated channel subfamily A member 2 blocker
1
1
4.7
GSR Glutathione reductase, mitochondrial
5
1
4.65
KDM4E Lysine-specific demethylase 4E
1
1
4.58
ALOX12 Polyunsaturated fatty acid lipoxygenase ALOX12
6
1
4.58
DRD1 D(1A) dopamine receptor
2
1
4.5
MAPK1 Mitogen-activated protein kinase 1
62
1
4.44
AGTR1 Type-1 angiotensin II receptor
4
1
4.44
4.35
ABCB11 Bile salt export pump
3
4
4.43
FFP 4'-phosphopantetheinyl transferase ffp
0
1
4.43
SCN1A,SCN2A,... Sodium channel alpha subunits; brain (Types I, II, III)
0
1
4.43
SCN10A,SCN11... Sodium channel alpha subunit
0
1
4.4
CYP2D6 Cytochrome P450 2D6
6
1
4.35
KMT2A Histone-lysine N-methyltransferase 2A
5
1
4.34
IDO1 Indoleamine 2,3-dioxygenase 1
1
1
4.3
4.3
KCNH2 Voltage-gated inwardly rectifying potassium channel KCNH2
2
4
4.3
ABCG2 Broad substrate specificity ATP-binding cassette transporter ABCG2
9
1
4.12
PMP22 Peripheral myelin protein 22
1
1
4.1
5.21
KCNA5 Potassium voltage-gated channel subfamily A member 5 blocker
2
2
4.02
KCNA1 Potassium voltage-gated channel subfamily A member 1 blocker
1
2
GLRA1 Glycine receptor subunit alpha-1 antagonist
1
0
CACNB2 Voltage-dependent L-type calcium channel subunit beta-2 inhibitor
8
0
KCNC1 Voltage-gated potassium channel KCNC1 blocker
1
0
GLRB Glycine receptor subunit beta antagonist
1
0
NR1I2 Nuclear receptor subfamily 1 group I member 2 agonist
2
0
GLRA3 Glycine receptor subunit alpha-3 antagonist
1
0
CALM1 Calmodulin-1 inhibitor
54
0
KCND3 A-type voltage-gated potassium channel KCND3 inhibitor
2
0
TRPM3 Transient receptor potential cation channel subfamily M member 3 activator
1
0
CACNA1G,CACN... Voltage-gated T-type calcium channel inhibitor
0
0
Target pathways
297
Abacavir transmembrane transport
R-HSA-2161517
ABCG2
ABC-family proteins mediated transport
R-HSA-382556
ABCC4
Activation of AMPK downstream of NMDARs
R-HSA-9619483
CALM1
MAPT
Activation of Ca-permeable Kainate Receptor
R-HSA-451308
CALM1
Activation of NF-kappaB in B cells
R-HSA-1169091
NFKB1
Activation of RAC1 downstream of NMDARs
R-HSA-9619229
CALM1
Activation of the AP-1 family of transcription factors
R-HSA-450341
MAPK1
Activation of the pre-replicative complex
R-HSA-68962
GMNN
Adenosine P1 receptors
R-HSA-417973
ADORA2A
ADORA3
ADORA1
Adrenaline,noradrenaline inhibits insulin secretion
R-HSA-400042
CACNA1D
CACNB2
CACNA1C
Advanced glycosylation endproduct receptor signaling
R-HSA-879415
MAPK1
Aflatoxin activation and detoxification
R-HSA-5423646
CYP1A2
CYP3A4
Amino acids regulate mTORC1
R-HSA-9639288
MTOR
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-983695
CALM1
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2
R-HSA-211957
CYP1A2
Aspirin ADME
R-HSA-9749641
BCHE
CYP2C19
CYP2D6
CYP2C9
CYP3A4
Assembly of the pre-replicative complex
R-HSA-68867
GMNN
Atorvastatin ADME
R-HSA-9754706
CYP3A4
Azathioprine ADME
R-HSA-9748787
ABCC4
Beta defensins
R-HSA-1461957
CCR2
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB
R-HSA-141333
MAOA
Biosynthesis of D-series resolvins
R-HSA-9018676
HPGD
Biosynthesis of DHA-derived SPMs
R-HSA-9018677
ALOX15
ALOX12
Biosynthesis of DPAn-3-derived maresins
R-HSA-9026290
ALOX12
Biosynthesis of DPAn-3-derived protectins and resolvins
R-HSA-9026286
ALOX15
Biosynthesis of DPAn-6 SPMs
R-HSA-9025106
ALOX15
ALOX12
Biosynthesis of E-series 18(R)-resolvins
R-HSA-9023661
ALOX15
Biosynthesis of E-series 18(S)-resolvins
R-HSA-9018896
HPGD
ALOX15
Biosynthesis of Lipoxins (LX)
R-HSA-2142700
HPGD
ALOX12
Biosynthesis of maresin-like SPMs
R-HSA-9027307
CYP1A2
CYP2D6
CYP2C9
CYP3A4
Biosynthesis of protectins
R-HSA-9018681
CYP1A2
ALOX15
Branched-chain amino acid catabolism
R-HSA-70895
HSD17B10
Breakdown of the nuclear lamina
R-HSA-352238
LMNA
Ca2+ pathway
R-HSA-4086398
CALM1
Calcineurin activates NFAT
R-HSA-2025928
CALM1
Calmodulin induced events
R-HSA-111933
CALM1
CaM pathway
R-HSA-111997
CALM1
Cam-PDE 1 activation
R-HSA-111957
CALM1
CaMK IV-mediated phosphorylation of CREB
R-HSA-111932
CALM1
Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856825
AGTR1
Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-264870
MAPT
CD209 (DC-SIGN) signaling
R-HSA-5621575
NFKB1
CD28 dependent PI3K/Akt signaling
R-HSA-389357
MTOR
Cellular response to hypoxia
R-HSA-1234174
HIF1A
Chemokine receptors bind chemokines
R-HSA-380108
CCR2
Ciprofloxacin ADME
R-HSA-9793528
ABCG2
Circadian Clock
R-HSA-400253
HIF1A
Clathrin-mediated endocytosis
R-HSA-8856828
AGTR1
CLEC7A (Dectin-1) induces NFAT activation
R-HSA-5607763
CALM1
CLEC7A (Dectin-1) signaling
R-HSA-5607764
NFKB1
CLEC7A/inflammasome pathway
R-HSA-5660668
NFKB1
Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-5674400
MTOR
CREB1 phosphorylation through the activation of Adenylate Cyclase
R-HSA-442720
CALM1
CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
R-HSA-442729
CALM1
CYP2E1 reactions
R-HSA-211999
CYP2C19
CYP2D6
CYP2C9
DARPP-32 events
R-HSA-180024
CALM1
Defective ABCB11 causes PFIC2 and BRIC2
R-HSA-5678520
ABCB11
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
R-HSA-9704331
BLM
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
R-HSA-9704646
BLM
Defective homologous recombination repair (HRR) due to BRCA1 loss of function
R-HSA-9701192
BLM
Defective MAOA causes BRUNS
R-HSA-5579012
MAOA
Defective TBXAS1 causes GHDD
R-HSA-5579032
TBXAS1
Depolymerization of the Nuclear Lamina
R-HSA-4419969
LMNA
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-8862803
LMNA
Detoxification of Reactive Oxygen Species
R-HSA-3299685
GSR
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-3134963
NFKB1
Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
R-HSA-9725554
ABCG2
Dopamine clearance from the synaptic cleft
R-HSA-379401
MAOA
Dopamine receptors
R-HSA-390651
DRD1
Downregulation of SMAD2/3:SMAD4 transcriptional activity
R-HSA-2173795
MAPK1
Downstream TCR signaling
R-HSA-202424
NFKB1
EGR2 and SOX10-mediated initiation of Schwann cell myelination
R-HSA-9619665
PMP22
Eicosanoids
R-HSA-211979
TBXAS1
Energy dependent regulation of mTOR by LKB1-AMPK
R-HSA-380972
MTOR
eNOS activation
R-HSA-203615
CALM1
Enzymatic degradation of dopamine by COMT
R-HSA-379397
MAOA
Enzymatic degradation of Dopamine by monoamine oxidase
R-HSA-379398
MAOA
ERK/MAPK targets
R-HSA-198753
MAPK1
ERKs are inactivated
R-HSA-202670
MAPK1
ESR-mediated signaling
R-HSA-8939211
MAPK1
Estrogen-dependent nuclear events downstream of ESR-membrane signaling
R-HSA-9634638
MAPK1
Estrogen-stimulated signaling through PRKCZ
R-HSA-9634635
MAPK1
Ethanol oxidation
R-HSA-71384
ALDH1A1
Extra-nuclear estrogen signaling
R-HSA-9009391
CALM1
Fatty acids
R-HSA-211935
CYP2D6
CYP2J2
FCERI mediated Ca+2 mobilization
R-HSA-2871809
CALM1
FCERI mediated MAPK activation
R-HSA-2871796
MAPK1
FCERI mediated NF-kB activation
R-HSA-2871837
NFKB1
FCGR3A-mediated IL10 synthesis
R-HSA-9664323
CALM1
FCGR3A-mediated phagocytosis
R-HSA-9664422
MAPK1
Formation of WDR5-containing histone-modifying complexes
R-HSA-9772755
KMT2A
Frs2-mediated activation
R-HSA-170968
MAPK1
Fructose catabolism
R-HSA-70350
ALDH1A1
G alpha (i) signalling events
R-HSA-418594
OPRM1
CCR2
ADORA3
ADORA1
G alpha (q) signalling events
R-HSA-416476
HTR2C
CHRM1
AGTR1
HTR2B
G alpha (s) signalling events
R-HSA-418555
TSHR
ADORA2A
DRD1
G-protein activation
R-HSA-202040
OPRM1
G2/M DNA damage checkpoint
R-HSA-69473
BLM
Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-881907
MAPK1
Glycogen breakdown (glycogenolysis)
R-HSA-70221
CALM1
Golgi Cisternae Pericentriolar Stack Reorganization
R-HSA-162658
MAPK1
Growth hormone receptor signaling
R-HSA-982772
MAPK1
HCMV Early Events
R-HSA-9609690
NFKB1
HDR through Homologous Recombination (HRR)
R-HSA-5685942
BLM
HDR through Single Strand Annealing (SSA)
R-HSA-5685938
BLM
Heme biosynthesis
R-HSA-189451
ABCG2
Heme degradation
R-HSA-189483
ABCG2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
R-HSA-9856530
CALM1
MTOR
Homologous DNA Pairing and Strand Exchange
R-HSA-5693579
BLM
Hormone ligand-binding receptors
R-HSA-375281
TSHR
HSF1-dependent transactivation
R-HSA-3371571
MTOR
IFNG signaling activates MAPKs
R-HSA-9732724
MAPK1
IkBA variant leads to EDA-ID
R-HSA-5603029
NFKB1
Impaired BRCA2 binding to PALB2
R-HSA-9709603
BLM
Impaired BRCA2 binding to RAD51
R-HSA-9709570
BLM
Inactivation, recovery and regulation of the phototransduction cascade
R-HSA-2514859
CALM1
Initiation of Nuclear Envelope (NE) Reformation
R-HSA-2995383
LMNA
Interaction between L1 and Ankyrins
R-HSA-445095
SCN5A
Interconversion of nucleotide di- and triphosphates
R-HSA-499943
GSR
Interferon gamma signaling
R-HSA-877300
MAPK1
Interleukin-1 processing
R-HSA-448706
NFKB1
Interleukin-1 signaling
R-HSA-9020702
NFKB1
Interleukin-10 signaling
R-HSA-6783783
CCR2
Interleukin-4 and Interleukin-13 signaling
R-HSA-6785807
HIF1A
OPRM1
ALOX15
RORC
MAOA
Ion homeostasis
R-HSA-5578775
CALM1
Ion transport by P-type ATPases
R-HSA-936837
CALM1
Iron uptake and transport
R-HSA-917937
ABCG2
Long-term potentiation
R-HSA-9620244
CALM1
Loss of phosphorylation of MECP2 at T308
R-HSA-9022535
CALM1
Macroautophagy
R-HSA-1632852
MTOR
MAP2K and MAPK activation
R-HSA-5674135
MAPK1
MAP3K8 (TPL2)-dependent MAPK1/3 activation
R-HSA-5684264
NFKB1
MAPK1 (ERK2) activation
R-HSA-112411
MAPK1
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
R-HSA-9856532
CACNB2
MECP2 regulates neuronal receptors and channels
R-HSA-9022699
OPRM1
Meiotic recombination
R-HSA-912446
BLM
Meiotic synapsis
R-HSA-1221632
LMNA
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se
R-HSA-2408550
GSR
Metabolism of serotonin
R-HSA-380612
MAOA
Methylation
R-HSA-156581
CYP1A2
Miscellaneous substrates
R-HSA-211958
CYP2D6
Mitochondrial protein degradation
R-HSA-9837999
HSD17B10
MTOR signalling
R-HSA-165159
MTOR
mTORC1-mediated signalling
R-HSA-166208
MTOR
Muscarinic acetylcholine receptors
R-HSA-390648
CHRM1
NCAM signaling for neurite out-growth
R-HSA-375165
MAPK1
NCAM1 interactions
R-HSA-419037
CACNA1D
CACNB2
CACNA1S
CACNA1C
Neddylation
R-HSA-8951664
HIF1A
Negative feedback regulation of MAPK pathway
R-HSA-5674499
MAPK1
Negative regulation of FGFR1 signaling
R-HSA-5654726
MAPK1
Negative regulation of FGFR2 signaling
R-HSA-5654727
MAPK1
Negative regulation of FGFR3 signaling
R-HSA-5654732
MAPK1
Negative regulation of FGFR4 signaling
R-HSA-5654733
MAPK1
Negative regulation of MAPK pathway
R-HSA-5675221
MAPK1
Negative regulation of NMDA receptor-mediated neuronal transmission
R-HSA-9617324
CALM1
Neurotransmitter clearance
R-HSA-112311
BCHE
ACHE
Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112314
GLRB
GLRA3
GLRA1
Neutrophil degranulation
R-HSA-6798695
MAPK1
NFKB1
NF-kB is activated and signals survival
R-HSA-209560
NFKB1
NFE2L2 regulating anti-oxidant/detoxification enzymes
R-HSA-9818027
GSR
NFE2L2 regulating MDR associated enzymes
R-HSA-9818032
ABCG2
NGF-independant TRKA activation
R-HSA-187024
ADORA2A
Norepinephrine Neurotransmitter Release Cycle
R-HSA-181430
MAOA
NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2122947
HIF1A
NPAS4 regulates expression of target genes
R-HSA-9768919
MAPK1
Nuclear Envelope Breakdown
R-HSA-2980766
LMNA
Nuclear events stimulated by ALK signaling in cancer
R-HSA-9725371
MAPK1
Nuclear Receptor transcription pathway
R-HSA-383280
NR1I2
RORC
Oncogene Induced Senescence
R-HSA-2559585
MAPK1
Opioid Signalling
R-HSA-111885
OPRM1
Oxidative Stress Induced Senescence
R-HSA-2559580
MAPK1
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
R-HSA-1234176
HIF1A
Paracetamol ADME
R-HSA-9753281
ABCC4
ABCG2
Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-6802955
CALM1
MAPK1
Peptide ligand-binding receptors
R-HSA-375276
OPRM1
AGTR1
Phase 0 - rapid depolarisation
R-HSA-5576892
SCN5A
CACNB2
CALM1
CACNA1C
Phase 1 - inactivation of fast Na+ channels
R-HSA-5576894
KCND3
Phase 2 - plateau phase
R-HSA-5576893
CACNB2
CACNA1C
Phase 3 - rapid repolarisation
R-HSA-5576890
KCNA5
KCNH2
Phase I - Functionalization of compounds
R-HSA-211945
CYP3A4
phospho-PLA2 pathway
R-HSA-111995
MAPK1
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-6811558
MAPK1
PIP3 activates AKT signaling
R-HSA-1257604
MTOR
PKA activation
R-HSA-163615
CALM1
PKMTs methylate histone lysines
R-HSA-3214841
KMT2A
NFKB1
PKR-mediated signaling
R-HSA-9833482
MAPT
Platelet Aggregation (Plug Formation)
R-HSA-76009
THPO
Platelet degranulation
R-HSA-114608
ABCC4
CALM1
Prednisone ADME
R-HSA-9757110
CYP3A4
Presynaptic depolarization and calcium channel opening
R-HSA-112308
CACNB2
Presynaptic phase of homologous DNA pairing and strand exchange
R-HSA-5693616
BLM
Processing of DNA double-strand break ends
R-HSA-5693607
BLM
Processive synthesis on the C-strand of the telomere
R-HSA-174414
BLM
Protein methylation
R-HSA-8876725
CALM1
PTK6 Expression
R-HSA-8849473
HIF1A
PTK6 promotes HIF1A stabilization
R-HSA-8857538
HIF1A
Purinergic signaling in leishmaniasis infection
R-HSA-9660826
NFKB1
RA biosynthesis pathway
R-HSA-5365859
ALDH1A1
RAF activation
R-HSA-5673000
CALM1
RAF-independent MAPK1/3 activation
R-HSA-112409
MAPK1
RAF/MAP kinase cascade
R-HSA-5673001
CALM1
MAPK1
Ras activation upon Ca2+ influx through NMDA receptor
R-HSA-442982
CALM1
RAS processing
R-HSA-9648002
CALM1
Recycling of bile acids and salts
R-HSA-159418
ABCB11
Recycling pathway of L1
R-HSA-437239
MAPK1
Reduction of cytosolic Ca++ levels
R-HSA-418359
CALM1
Regulated proteolysis of p75NTR
R-HSA-193692
NFKB1
Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029482
MAPK1
Regulation of gene expression by Hypoxia-inducible Factor
R-HSA-1234158
HIF1A
Regulation of HSF1-mediated heat shock response
R-HSA-3371453
MAPK1
Regulation of insulin secretion
R-HSA-422356
CACNA1D
CACNB2
CACNA1C
Regulation of MECP2 expression and activity
R-HSA-9022692
CALM1
Regulation of NFE2L2 gene expression
R-HSA-9818749
NFKB1
Regulation of PTEN gene transcription
R-HSA-8943724
MAPK1
MTOR
Regulation of the apoptosome activity
R-HSA-9627069
MAPK1
Regulation of TP53 Activity through Phosphorylation
R-HSA-6804756
BLM
Regulation of TP53 Degradation
R-HSA-6804757
MTOR
Resolution of D-loop Structures through Holliday Junction Intermediates
R-HSA-5693568
BLM
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
R-HSA-5693554
BLM
RHO GTPases activate IQGAPs
R-HSA-5626467
CALM1
RHO GTPases Activate NADPH Oxidases
R-HSA-5668599
MAPK1
RHO GTPases activate PAKs
R-HSA-5627123
MYLK
CALM1
RHO GTPases Activate WASPs and WAVEs
R-HSA-5663213
MAPK1
RIP-mediated NFkB activation via ZBP1
R-HSA-1810476
NFKB1
rRNA processing in the mitochondrion
R-HSA-8868766
HSD17B10
RSK activation
R-HSA-444257
MAPK1
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
R-HSA-8936459
KMT2A
RUNX1 regulates transcription of genes involved in differentiation of HSCs
R-HSA-8939236
KMT2A
RUNX2 regulates osteoblast differentiation
R-HSA-8940973
MAPK1
RUNX3 Regulates Immune Response and Cell Migration
R-HSA-8949275
RORC
SARS-CoV-1 activates/modulates innate immune responses
R-HSA-9692916
NFKB1
SARS-CoV-2 modulates host translation machinery
R-HSA-9754678
SMN1
Senescence-Associated Secretory Phenotype (SASP)
R-HSA-2559582
MAPK1
NFKB1
Sensory processing of sound by inner hair cells of the cochlea
R-HSA-9662360
CACNA1D
CACNB2
Serotonin receptors
R-HSA-390666
HTR2C
HTR2B
Signal attenuation
R-HSA-74749
MAPK1
Signal transduction by L1
R-HSA-445144
MAPK1
Signaling by Activin
R-HSA-1502540
MAPK1
Signaling by BRAF and RAF1 fusions
R-HSA-6802952
LMNA
CALM1
MAPK1
Signaling by high-kinase activity BRAF mutants
R-HSA-6802948
MAPK1
Signaling by LTK in cancer
R-HSA-9842640
MAPK1
Signaling by MAP2K mutants
R-HSA-9652169
MAPK1
Signaling by MAPK mutants
R-HSA-9652817
MAPK1
Signaling by moderate kinase activity BRAF mutants
R-HSA-6802946
CALM1
MAPK1
Signaling by NODAL
R-HSA-1181150
MAPK1
Signaling by RAF1 mutants
R-HSA-9656223
CALM1
MAPK1
Signaling downstream of RAS mutants
R-HSA-9649948
CALM1
MAPK1
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2173796
MAPK1
Smooth Muscle Contraction
R-HSA-445355
MYLK
CALM1
snRNP Assembly
R-HSA-191859
SMN1
Sodium/Calcium exchangers
R-HSA-425561
CALM1
Sphingolipid de novo biosynthesis
R-HSA-1660661
ABCG2
Spry regulation of FGF signaling
R-HSA-1295596
MAPK1
STAT3 nuclear events downstream of ALK signaling
R-HSA-9701898
HIF1A
Stimuli-sensing channels
R-HSA-2672351
CALM1
SUMOylation of DNA damage response and repair proteins
R-HSA-3108214
BLM
SUMOylation of intracellular receptors
R-HSA-4090294
NR1I2
Suppression of apoptosis
R-HSA-9635465
MAPK1
Surfactant metabolism
R-HSA-5683826
ADORA2A
Switching of origins to a post-replicative state
R-HSA-69052
GMNN
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
R-HSA-2142816
CYP2C19
CYP1A2
CYP2C9
Synthesis of 12-eicosatetraenoic acid derivatives
R-HSA-2142712
ALOX15
ALOX12
Synthesis of 15-eicosatetraenoic acid derivatives
R-HSA-2142770
ALOX15
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
R-HSA-193368
ABCB11
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
R-HSA-2142670
CYP2C19
CYP1A2
CYP2C9
CYP2J2
Synthesis of Hepoxilins (HX) and Trioxilins (TrX)
R-HSA-2142696
ALOX12
Synthesis of IP3 and IP4 in the cytosol
R-HSA-1855204
CALM1
Synthesis of Leukotrienes (LT) and Eoxins (EX)
R-HSA-2142691
ALOX15
Synthesis of PC
R-HSA-1483191
BCHE
ACHE
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
R-HSA-2162123
HPGD
TBXAS1
Synthesis, secretion, and deacylation of Ghrelin
R-HSA-422085
BCHE
ACHE
TAK1-dependent IKK and NF-kappa-B activation
R-HSA-445989
NFKB1
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
R-HSA-1474151
CALM1
The NLRP3 inflammasome
R-HSA-844456
NFKB1
Thrombin signalling through proteinase activated receptors (PARs)
R-HSA-456926
MAPK1
TP53 Regulates Metabolic Genes
R-HSA-5628897
GSR
MTOR
TRAF6 mediated NF-kB activation
R-HSA-933542
NFKB1
Transcriptional activation of mitochondrial biogenesis
R-HSA-2151201
CALM1
Transcriptional and post-translational regulation of MITF-M expression and activity
R-HSA-9856649
MAPK1
Transcriptional Regulation by VENTX
R-HSA-8853884
NFKB1
Transcriptional regulation of granulopoiesis
R-HSA-9616222
KMT2A
Transcriptional regulation of white adipocyte differentiation
R-HSA-381340
NFKB1
Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-1445148
CALM1
tRNA modification in the mitochondrion
R-HSA-6787450
HSD17B10
tRNA processing in the mitochondrion
R-HSA-6785470
HSD17B10
TRP channels
R-HSA-3295583
TRPA1
TRPM3
Tryptophan catabolism
R-HSA-71240
IDO2
IDO1
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
R-HSA-9860927
NFKB1
Ub-specific processing proteases
R-HSA-5689880
HIF1A
Unblocking of NMDA receptors, glutamate binding and activation
R-HSA-438066
CALM1
Uptake and function of anthrax toxins
R-HSA-5210891
CALM1
VEGFR2 mediated cell proliferation
R-HSA-5218921
CALM1
VEGFR2 mediated vascular permeability
R-HSA-5218920
CALM1
MTOR
Voltage gated Potassium channels
R-HSA-1296072
KCNA1
KCNA7
KCNA5
KCND3
KCNC1
KCNH2
KCNA2
XBP1(S) activates chaperone genes
R-HSA-381038
LMNA
Xenobiotics
R-HSA-211981
CYP2C19
CYP2D6
CYP2C9
CYP2J2
CYP3A4
Zygotic genome activation (ZGA)
R-HSA-9819196
KDM4E
References
98
2023 A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.
Sutherland JJ, Yonchev D et al. Nat Commun
2023 Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species.
Sidhom PA, El-Bastawissy E et al. J Med Chem
2022 Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Zattoni IF, Delabio LC et al. Eur J Med Chem
2022 Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
Huang MX, Tian YJ et al. J Med Chem
Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity (dataset)
2019 New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition.
Malek R, Arribas RL et al. J Med Chem
2019 Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J, Jang S et al. Bioorg Med Chem Lett
2019 Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
González-Hernández E, Aparicio R et al. MedChemComm
2017 Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.
Steiger SA, Li C et al. Bioorg Med Chem
2017 A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.
Al-Sabi A, Daly D et al. J Med Chem
2016 Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Vivier D, Bennis K et al. J. Med. Chem.
2015 Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers.
Chikhale R, Thorat S et al. Bioorg. Med. Chem.
2014 New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury.
Tenti G, Parada E et al. J. Med. Chem.
2014 Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Aleo MD, Luo Y et al. Hepatology
2013 Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Ren S; Zeng J et al.
2013 Discovery of coumarin-dihydropyridine hybrids as bone anabolic agents.
Sashidhara KV, Kumar M et al. J. Med. Chem.
2013 MICE models: superior to the HERG model in predicting Torsade de Pointes.
Kramer J, Obejero-Paz CA et al. Scientific Reports
2013 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE, van Staden CJ et al. Toxicol Sci
2012 Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Wiśniowska B; Mendyk A et al.
2012 Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²¿ channel blockers with analgesic activity.
Beebe X, Darczak D et al. Bioorg. Med. Chem.
2012 Synthesis of a New Series of 4-Aryl-1,4-Dihydropyridines with Calcium Channel Blocking and Vasodilatory Activity
Bansal R, Jain P et al. Med Chem Res
2012 Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA et al.
2012 Synthesis, calcium-channel blocking activity, and conformational analysis of some novel 1,4-dihydropyridines: application of PM3 and DFT computational methods
Fassihi A, Mahnam K et al. Med Chem Res
2012 Synthesis and calcium channel antagonist activity of novel 1,4-dihydropyridine derivatives possessing 4-pyrone moieties
Shahrisa A, Miri R et al. Med Chem Res
2012 In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Dawson S, Stahl S et al. Drug Metab. Dispos.
2012 Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Warner DJ, Chen H et al. Drug Metab Dispos
2011 Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
Bass JY, Caravella JA et al. Bioorg. Med. Chem. Lett.
2011 Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Sinha N; Sen S
2011 Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR, Cui Y et al. Cardiovasc. Res.
2011 Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors.
Çakmak R; Durdagi S et al.
2010 Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
Baraldi PG, Preti D et al. J. Med. Chem.
2010 Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
Reimão JQ, Scotti MT et al. Bioorg. Med. Chem.
2009 Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
Sinnegger-Brauns MJ, Huber IG et al. Mol. Pharmacol.
2009 Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Roy K, Pratim Roy P. Eur. J. Med. Chem.
2009 Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Yuan J, Johnson RL et al. Nat. Chem. Biol.
2009 Lipophilic 2-(4-chlorophenyl)-4-thiazolyl-1,4-dihydropyridines: synthesis, calcium channel antagonist activity, and protection against pentylenetetrazole-induced seizure
Samzadeh-Kermani A, Shafaroodi H et al. Med Chem Res
2008 Support vector machines classification of hERG liabilities based on atom types.
Jia L; Sun H
2008 Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).
Vaccaro W, Huynh T et al. Bioorg. Med. Chem. Lett.
2005 A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Tobita M; Nishikawa T et al.
2005 Qsar for Acetylcholinesterase and Butyrylcholinesterase Inhibition by Cardiovascular Drugs and Benzodiazepines
Chiou S, Lai G et al. Med Chem Res
2004 The CACNA1F gene encodes an L-type calcium channel with unique biophysical properties and tissue distribution.
McRory JE, Hamid J et al. J. Neurosci.
2004 Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
Shan R, Velazquez C et al. J. Med. Chem.
2004 The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Du LP; Tsai KC et al.
2003 Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).
Chougnet A, Stoessel C et al. Bioorg. Med. Chem. Lett.
2003 Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Keserü GM Bioorg. Med. Chem. Lett.
2003 4-Phenyl-4H-pyrans as IK(Ca) channel blockers.
Urbahns K, Horvath E et al. Bioorg. Med. Chem. Lett.
2002 Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.
Takara K, Sakaeda T et al. Eur. J. Pharm. Sci.
2001 Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E, Lew K et al. Chem. Res. Toxicol.
2000 Characterization of nifedipine-resistant calcium current in neonatal rat ventricular cardiomyocytes.
Pignier C, Potreau D Am. J. Physiol. Heart Circ. Physiol.
1998 Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction.
Bertilsson G, Heidrich J et al. Proc. Natl. Acad. Sci. U.S.A.
1998 Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
Kalman K, Nguyen A et al. J. Biol. Chem.
1998 New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities.
Di Stilo A, Visentin S et al. J. Med. Chem.
1998 Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
Ramesh M, Matowe WC et al. J. Med. Chem.
1998 Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates.
Iqbal N, Akula MR et al. J. Med. Chem.
1997 Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
Jiang Q; Lee BX et al.
1996 Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
Cho H, Katoh S et al. J. Med. Chem.
1996 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.
Jiang JL, van Rhee AM et al. J Med Chem
1996 Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
van Rhee AM, Jiang JL et al. J Med Chem
1995 Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators.
Rovnyak GC, Kimball SD et al. J. Med. Chem.
1994 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Grissmer S, Nguyen AN et al. Mol. Pharmacol.
1993 Vascular selectivity of seven prototype calcium antagonists: a study at the single cell level.
Pérez-Vizcaíno F, Tamargo J et al. J. Cardiovasc. Pharmacol.
1993 Novel heterocyclic analogues of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
Gubin J, de Vogelaer H et al. J. Med. Chem.
1993 Isosteric replacement in a series of -substituted monophosphonate calcium antagonists
Poindexter GS, Foley MA et al. Bioorg. Med. Chem. Lett.
1993 Preparation and in vitro biological evaluation of the enantiomers of the diydropyridine BMY 20014, a combination calcium and 1-adrenoreceptor antagonist
Lawson JE, Poindexter GS et al. Bioorg. Med. Chem. Lett.
1993 Imidazol-1-yl and pyridin-3-yl derivatives of 4-phenyl-1,4-dihydropyridines combining Ca2+ antagonism and thromboxane A2 synthase inhibition.
Cozzi P, Carganico G et al. J. Med. Chem.
1993 A homologous series of permanently charged 1,4-dihydropyridines: novel probes designed to localize drug binding sites on ion channels.
Baindur N, Rutledge A et al. J. Med. Chem.
1993 Polycyclic guanidine alkaloids from the marine sponge Crambe crambe and Ca++ channel blocker activity of crambescidin 816.
Berlinck RG, Braekman JC et al. J. Nat. Prod.
1992 The discovery of a novel calcium channel blocker related to the structure of potassium channel opener cromakalim
Atwal KS, McCullough JR et al. Bioorg. Med. Chem. Lett.
1992 A novel class of calcium-entry blockers: the 1[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
Gubin J, Lucchetti J et al. J. Med. Chem.
1992 Synthesis, configuration, and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates.
Rose U, Dräger M. J. Med. Chem.
1992 Synthesis of 3-[(2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl] 1,4-dihydropyridine-3,5-dicarboxylate derivatives as calcium channel modulators.
Sunkel CE, Fau de Casa-Juana M et al. J. Med. Chem.
1992 Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
Rovnyak GC, Atwal KS et al. J. Med. Chem.
1991 A new class of calcium antagonists. 2. Synthesis and biological activity of 11-[[4-[4-(4-fluorophenyl)-1-piperazinyl]butyryl]amino]-6,11- dihydrodibenzo[b,e]-thiepin maleate and related compounds.
Kurokawa M, Sato F et al. J. Med. Chem.
1991 Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
Alker D, Campbell SF et al. J. Med. Chem.
1991 Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
Mason RP, Rhodes DG et al. J. Med. Chem.
1991 Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.
Atwal KS, Swanson BN et al. J. Med. Chem.
1991 Dihydropyrimidine calcium channel blockers 51: bicyclic dihydropyrimidines as potent mimics of dihydropyridines
Atwal KS, Moreland S Bioorg. Med. Chem. Lett.
1991 Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
Shanklin JR, Johnson CP et al. J. Med. Chem.
1990 Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.
Alker D, Campbell SF et al. J. Med. Chem.
1990 Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
Alker D, Campbell SF et al. J. Med. Chem.
1990 Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
Buckle DR, Arch JR et al. J. Med. Chem.
1989 Long-acting dihydropyridine calcium antagonists. 3. Synthesis and structure-activity relationships for a series of 2-[(heterocyclylmethoxy)methyl] derivatives.
Alker D, Campbell SF et al. J. Med. Chem.
1989 Long acting dihydropyridine calcium antagonists. 2. 2-[2-Aminoheterocycloethoxy]methyl derivatives.
Arrowsmith JE, Campbell SF et al. J. Med. Chem.
1989 Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity.
Cho H, Ueda M et al. J. Med. Chem.
1988 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach.
Coburn RA, Wierzba M et al. J. Med. Chem.
1988 Synthesis of (aryloxy)alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity.
Sanfilippo PJ, Urbanski M et al. J. Med. Chem.
1988 Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines.
Sunkel CE, Fau de Casa-Juana M et al. J. Med. Chem.
1988 2-(2-Aryl-2-oxoethylidene)-1,2,3,4-tetrahydropyridines. Novel isomers of 1,4-dihydropyridine calcium channel blockers.
Taylor MD, Badger EW et al. J. Med. Chem.
1988 Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers.
Rovnyak G, Andersen N et al. J. Med. Chem.
1987 Calcium currents, charge movement and dihydropyridine binding in fast- and slow-twitch muscles of rat and rabbit.
Lamb GD, Walsh T J. Physiol. (Lond.)
1987 Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformation.
Baldwin JJ, Claremon DA et al. J. Med. Chem.
1987 Synthesis and biological activity of novel calcium channel blockers: 2,5-dihydro-4-methyl-2-phenyl-1,5-benzothiazepine-3-carboxylic acid esters and 2,5-dihydro-4-methyl-2-phenyl-1,5-benzodiazepine-3-carboxylic acid esters.
Atwal KS, Bergey JL et al. J. Med. Chem.
1986 Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
Arrowsmith JE, Campbell SF et al. J. Med. Chem.
1986 Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.
Tamazawa K, Arima H et al. J. Med. Chem.
1985 A new class of cardiotonic agents: structure-activity correlations for natural and synthetic analogues of the alkaloid A new class of A new class of cardiotonic agents: structure-activity correlations for natural and synthetic analogues of the alkaloid pumiliotoxin B (8-hydroxy-8-methyl-6-alkylidene-1-azabicyclo[4.3.0]nonanes).
Daly JW, McNeal ET et al. J. Med. Chem.
1985 [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
McNeal ET, Lewandowski GA et al. J. Med. Chem.
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease: Purified N370S Glucocerebrosidase. (Class of assay: confirmatory) [Related pubchem assays: 2101 ] AID 2597
DrugMatrix in vitro pharmacology data (dataset)
Cell lines
5
6
C6-BU-1
5.81
Calvarial osteoblast
5.03
HepG2
4.3
Lymphoblastoid cell
4.24
MM1.S
Organisms
7
8.44
Rattus norvegicus
8.44
Sus scrofa
8.29
Cavia porcellus
6.7
Oryctolagus cuniculus
4.9
Plasmodium falciparum
4.84
Saccharomyces cerevisiae
4.02
Leishmania braziliensis
Compound Sets
38
AdooQ Bioactive Compound Library
A10643
Axon Medchem Screening Library
2068
Cayman Chemical Bioactives
11106
25510
ChEMBL Approved Drugs
CHEMBL193
ChEMBL Drugs
CHEMBL193
Concise Guide to Pharmacology 2017/18
2514
Concise Guide to Pharmacology 2019/20
2514
Concise Guide to Pharmacology 2021/22
2514
Concise Guide to Pharmacology 2023/24
2514
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01115
DrugBank Approved Drugs
DB01115
DrugCentral
1922
DrugCentral Approved Drugs
1922
DrugMAP
DMSVOZT
DrugMAP Approved Drugs
DMSVOZT
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101574
Guide to Pharmacology
2514
Ki Database
NIFEDIPINE
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL193
MedChem Express Bioactive Compound Library
HY-B0284
NCATS Inxight Approved Drugs
I9ZF7L6G2L
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2F78DD2792E0
nursa/index.jsf?doi=10.1621%2FRVZMIO1ZLJ
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Nifedipine(Adalat)
TargetMol Bioactive Compound Library
T1146
The Spectrum Collection
Tocris Bioactive Compound Library
1075
Tocriscreen Total
Withdrawn 2.0
w55
ZINC Tool Compounds
ZINC000085205448
Available from
14
AdooQ Bioactive Compound Library
A10643
Axon Medchem Screening Library
2068
Cayman Chemical Bioactives
11106
25510
Enamine BioReference Compounds
LOPAC library
Mcule
MCULE-7336870265
MedChem Express Bioactive Compound Library
HY-B0284
MolPort
MolPort-000-787-707
Molport-000-787-707
MolPort-003-849-387
Molport-003-849-387
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
Nifedipine(Adalat)
TargetMol Bioactive Compound Library
T1146
The Spectrum Collection
Tocris Bioactive Compound Library
1075
Tocriscreen Total
External IDs
60
ChEMBL CHEMBL193
GtoPdb 2514
PubChem 4485 45040023
ZINC ZINC000085205448
ACToR 21829-25-4 101539-70-2
BindingDB 50101817
Brenda 127074 132142 125893 3738 224433 229727 229728
CCDC BICCIZ
ChEBI 7565
ChemSpider 4330
ClinicalTrials.gov AFEDITAB CR PROCARDIA NIFEDIPINE BAY-A-1040 CORACTEN BAY A 1040 ADALAT
COCONUT CNP0601416.0
CompTox DTXSID2025715 DTXSID40662146
DailyMed NIFEDIPINE
DrugBank DB01115
DrugCentral 1922
eMolecules 715726 26948255
FDA SRS I9ZF7L6G2L
GEA nifedipine
GSRS 8c58aff0-16c3-4...
HMDB HMDB15247 HMDB0015247
KEGG C07266
LINCS LSM-4176
Mcule MCULE-7336870265
MetaboLights MTBLC7565
MolPort MolPort-000-787-707 Molport-000-787-707 MolPort-003-849-387 Molport-003-849-387
NMRShiftDB 60021396
PDB C5U
PharmGKB PA450631
PubChem DOTF 12014071
PubChem TPS 14875984
Reactome 4330
Recon nifedipine
RxNorm NIFEDIPINE ADALAT PROCARDIA AFEDITAB CR
Selleck Nifedipine(Adalat)
SureChEMBL SCHEMBL3968 SCHEMBL20769057
Properties
(calculated by RDKit )
Molecular Weight
346.12
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
1
cLogP
2.18
TPSA
107.77
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
L-type
Target
Calcium Channel
CAM
Potassium Channel
CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3
Ca channel blocker
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Neuroscience
Autophagy
Primary Target
CaV1.x Channels (L-type)
MOA
Blocker
Calcium Channel Blockers
Antioxidants
"Calcium Channel Blockers
Antioxidants"
calcium channel blocker
Member status
member
Indication
vasospastic angina, chronic stable angina
ATC
C08CA05
Toxicity type
cardiovascular
Therapeutic Class
Analgesics
Source data